Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A)

[1]  E. Oki,et al.  Neoadjuvant Chemoradiotherapy for Patients with cT3/Nearly T4 Esophageal Cancer: Is Sarcopenia Correlated with Postoperative Complications and Prognosis? , 2018, World Journal of Surgery.

[2]  E. Oki,et al.  Sarcopenia is an independent predictor of complications after colorectal cancer surgery , 2018, Surgery Today.

[3]  Shiying Yu,et al.  Development and validation of a clinically applicable score to classify cachexia stages in advanced cancer patients , 2018, Journal of cachexia, sarcopenia and muscle.

[4]  H. Honda,et al.  Clinical Impact and Risk Factors for Skeletal Muscle Loss After Complete Resection of Early Non-small Cell Lung Cancer , 2018, Annals of Surgical Oncology.

[5]  F. Huang,et al.  Irisin stimulates cell proliferation and invasion by targeting the PI3K/AKT pathway in human hepatocellular carcinoma. , 2017, Biochemical and biophysical research communications.

[6]  F. Koga,et al.  Posttherapeutic skeletal muscle mass recovery predicts favorable prognosis in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. , 2017, Urologic oncology.

[7]  K. Muro,et al.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  R. White,et al.  Exercise-dependent regulation of the tumour microenvironment , 2017, Nature Reviews Cancer.

[9]  M. Endo,et al.  Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non–small-cell lung cancer , 2017, BMC Cancer.

[10]  E. Oki,et al.  A prospective study of XELIRI plus bevacizumab as a first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101) , 2017, International Journal of Clinical Oncology.

[11]  Hui Li,et al.  Irisin suppresses the migration, proliferation, and invasion of lung cancer cells via inhibition of epithelial-to-mesenchymal transition. , 2017, Biochemical and biophysical research communications.

[12]  E. Oki,et al.  Prognostic Significance of Sarcopenia in Patients with Esophagogastric Junction Cancer or Upper Gastric Cancer , 2017, Annals of Surgical Oncology.

[13]  Y. Maehara,et al.  Sarcopenia is a poor prognostic factor following hepatic resection in patients aged 70 years and older with hepatocellular carcinoma , 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

[14]  Marian A E de van der Schueren,et al.  Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Heather K. Neilson,et al.  Physical Activity and Cancer Outcomes: A Precision Medicine Approach , 2016, Clinical Cancer Research.

[16]  H. Muss,et al.  Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review. , 2016, European journal of cancer.

[17]  E. Oki,et al.  Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801) , 2016, International Journal of Clinical Oncology.

[18]  E. Oki,et al.  A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902) , 2015, International Journal of Clinical Oncology.

[19]  E. Oki,et al.  Phase II Trial of S-1 and Oxaliplatin Plus Cetuximab for Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases (KSCC1002) , 2015, Annals of Surgical Oncology.

[20]  Y. Sakamoto,et al.  Negative Impact of Skeletal Muscle Loss after Systemic Chemotherapy in Patients with Unresectable Colorectal Cancer , 2015, PloS one.

[21]  J. W. Kim,et al.  Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy , 2015, Supportive Care in Cancer.

[22]  M. Bisoffi,et al.  Effects of the exercise‐inducible myokine irisin on malignant and non‐malignant breast epithelial cell behavior in vitro , 2015, International journal of cancer.

[23]  E. Oki,et al.  Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab (KSCC0802 Study). , 2014, Anticancer research.

[24]  Julien Taieb,et al.  Sarcopenia Is Linked to Treatment Toxicity in Patients With Metastatic Colorectal Cancer , 2014, Nutrition and cancer.

[25]  E. Oki,et al.  Phase II Trial of Alternating mFOLFOX6 and FOLFIRI Regimens in the First-Line Treatment for Unresectable or Metastatic Colorectal Cancer (KSCC0701) , 2013, Oncology.

[26]  Y. Naito,et al.  A novel myokine, secreted protein acidic and rich in cysteine (SPARC), suppresses colon tumorigenesis via regular exercise , 2012, Gut.

[27]  Masahiro Yoshida,et al.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer , 2012, International Journal of Clinical Oncology.

[28]  I. Rosenberg.  Sarcopenia: origins and clinical relevance. , 2011, Clinics in geriatric medicine.

[29]  Paula Ravasco,et al.  Definition and classification of cancer cachexia: an international consensus. , 2011, The Lancet. Oncology.

[30]  J. Baeyens,et al.  Sarcopenia: European consensus on definition and diagnosis , 2010, Age and ageing.

[31]  M. Ducreux,et al.  Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Tony Reiman,et al.  A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. , 2008, Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme.

[33]  Tony Reiman,et al.  Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. , 2008, The Lancet. Oncology.

[34]  W. Scheithauer,et al.  Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  M. Yamagishi,et al.  Reassessment of the cutoff values of waist circumference and visceral fat area for identifying Japanese subjects at risk for the metabolic syndrome. , 2008, Diabetes research and clinical practice.

[36]  C. Dejong,et al.  Pathophysiology of cancer cachexia: much more than host-tumour interaction? , 2007, Clinical nutrition.

[37]  Stanley Heshka,et al.  Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. , 2004, Journal of applied physiology.

[38]  L. Coussens,et al.  Inflammation and cancer , 2002, Nature.

[39]  P. Simmonds,et al.  Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis , 2000, BMJ : British Medical Journal.

[40]  F. López‐Soriano,et al.  The role of cytokines in cancer cachexia , 1999, Medicinal research reviews.

[41]  Christian Jacques,et al.  Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer , 1998, The Lancet.

[42]  S B Heymsfield,et al.  Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. , 1998, Journal of applied physiology.

[43]  K. Miller,et al.  Visceral abdominal-fat accumulation associated with use of indinavir , 1998, The Lancet.

[44]  I. Rosenberg,et al.  Sarcopenia: origins and clinical relevance. , 1997, The Journal of nutrition.

[45]  W. Scheithauer,et al.  Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. , 1993, BMJ.

[46]  J. Hankin.  Development of a diet history questionnaire for studies of older persons. , 1989, The American journal of clinical nutrition.

[47]  B. Barton.  IL-6-like cytokines and cancer cachexia , 2001, Immunologic research.

[48]  Epidemiologic and methodologic problems in determining nutritional status of older persons. Proceedings of a conference. Albuquerque, New Mexico, October 19-21, 1988. , 1989, The American journal of clinical nutrition.